• Background: Investigating the molecular mechanisms of bortezomib (BTZ) resistance in neuroblastoma cell models, the study analyzed cellular methylome profiles using precise molecular detection and assay products to evaluate treatment-induced methylation shifts and cellular survival pathways.

• Key Finding: The study demonstrates that bortezomib induces pronounced, genome-wide methylation changes in recovering neuroblastoma cells, which play a significant role in developing treatment-resistant and highly proliferative phenotypes.

• Conclusion: These insights underscore the critical utility of targeted molecular detection methods in oncology research, highlighting epigenetic modifications as key therapeutic targets to overcome acquired drug resistance in cancer therapy.

• Original Article & Authors: Published in Scientific Reports (2021) by lead researchers Katarzyna Buczkowska, Olga Taryma-Leśniak, Krzysztof Pastuszek, Anna Supernat, Justyna Chmielewska, Lena Lotte Hansen, Edyta Piekowska, Tomasz Wojdacz, and Bogusław Machalinski from Pomeranian Medical University and partners.

Read the full publication, see the link below ↓